Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin versus metformin in prediabetes
IRCT20220902055858N1Phase 3Completed
- Sponsor
- Shahrekord University of Medical Sciences
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of empagliflozin and metformin in prediabetes and impaired fasting glucose (IFG) (3 arms), sponsored by Shahrekord University of Medical Sciences. Primary endpoints: fasting blood sugar, serum fasting insulin and 8 more. Started Sep 2022; status: completed.
02
Drugs
empagliflozinmetformin
03
Conditions
prediabetesimpaired fasting glucose (IFG)
Beyond the preview
Go deeper on IRCT20220902055858N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220902055858N1.